Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem

Name: Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem
Uploaded: 2026-08-04T12:00:29.000Z
Duration: 47 min 22 s
Channel: Sequoia Capital

Sequoia CapitalAugust 4, 202647m

Topics38

Simplicity as a Core Principle0:00 Chai Discovery's Mission0:30 Engineering vs. Testing Boundary2:00 Evolution of the Field3:30 Progression from Protein Folding to Design5:00 Antibody Design Breakthrough6:00 Unified Framework for Biology7:00 Founding Team Backgrounds8:00 Right Time to Start the Company9:00 Why Diffusion Models Work10:00 Team Composition and Evolution12:00 Hiring Philosophy14:00 Engineering Standards14:30 Quality Improvements in Generated Molecules15:30 Rapid Progress and Scaling Philosophy17:30 Bitter Lesson Approach18:00 Building from Scratch19:00 Guiding Principles at Chai19:59 Verifiability of Model Progress21:00 Two Categories of Drug Discovery Targets22:31 Core Modeling Philosophy and Scaling Laws22:59 Different Definitions of Hard Targets Across Teams24:00 The Goal: A Computerated Design Suite for Molecules25:02 Future Vision: Industry in 2035-204026:30 Business Model: Infrastructure vs. Drug Development28:31 Surprises from Pharma Partnerships31:30 Data Sources and Compounding Effects33:01 Pragmatic Approach to Sequence vs. Structure36:00 Competitive Landscape and Staying at the Frontier37:30 Experience Requirements for Antibody Development38:56 Adoption Milestone Achievement39:30 Company Culture and Team Motivation40:00 Infrastructure Scaling Challenges40:30 Transition from Research to Production42:01 Production Quality Requirements43:01 Company Naming and Branding44:01 Near-Term Development Focus44:30 Technical Development Priorities46:01

In a Nutshell

Chai Discovery's core thesis is that drug design is fundamentally a scaling problem: by simplifying their AI architecture to a unified sequence-based model and scaling compute, data, and parameters, they've achieved a 150x improvement in zero-shot antibody design success rates (from 0.1% to 15% hit rates). The company is building infrastructure rather than drugs, treating biology as an engineering discipline where the goal is to specify desired molecular properties and have the model generate them directly, reducing the idea-to-testable-molecule timeline from 9 months to 9 days. This "bitter lesson" approach—scaling laws over bespoke solutions—has enabled them to reach commercial adoption with major pharma partners like Eli Lilly and Pfizer.

AI-Generated Notes

These notes were generated by AI and may contain inaccuracies.

One of the big guiding principles is simplicity. When looking at a model like Chai 1, there are 23 distinct submodules. Trying to iterate on something with that complexity becomes difficult because each submodule needs to be understood independently, including their behaviors and dynamics. This approach does not scale well. The focus shifts toward simplifying the system by identifying what is really important, which makes the research process and identifying scaling directions much simpler.

Chai is engineering molecules with AI and functions as a foundation model lab for biology. The big idea is to make the drug discovery process look more like engineering. Code generation with language models works well because code is a simple abstraction. Biology today is characterized by trial and error. Early modern biotech medicines were discovered randomly through serendipity. The goal is to industrialize the process by developing tools that create abstraction layers similar to those in code and modern engineering, enabling faster iteration in biology and drug discovery.

There is a boundary between what can be engineered and what needs to be tested in the real world. This boundary has been moving over time, with an increasing proportion of the drug development process becoming engineerable rather than reliant on trial and error. The lab serves as an important verification component. Verification is a major theme in AI as well. When a model can be evaluated and verified, progress can be made through hill climbing. The objective is to transform drug discovery into drug design. The term drug discovery reflects the current paradigm of screening millions or billions of molecules to find one that works. The vision is to input the desired molecule properties and have the model materialize it. This approach may not reduce lab testing and could potentially increase it, as higher ROI leads to greater demand, similar to how software engineers became more in demand after becoming more productive.

The field has evolved significantly over the last decade. The biannual protein folding competition involves holding out protein targets that have never been seen before and are not deposited publicly, with academic groups competing to predict protein structures. A significant step change in performance occurred in 2018, followed by another breakthrough in 2020 with AlphaFold 2. The advent of deep learning initiated this progress. Early systems predicted distances between amino acids in proteins and used a renderer to produce protein structures from noisy, incomplete distance information. With relatively minimal information, machine learning systems could produce proteins that were largely correct, though resolution was limited compared to current capabilities. The evolution paralleled early image generation models that were grainy and blurry, progressing to high-definition outputs.

Once protein folding became realizable, other sub-problems emerged. Given a protein structure, the task became designing a sequence that would fold to that structure, moving closer to the drug design problem. The focus shifted to engineering proteins that match specific shapes or perform specific functions. This work occurred around 2021-2022. The advent of diffusion models enabled simultaneous generation of protein structure and sequence. Prompts became increasingly realistic, allowing models to be prompted on targets with specific shapes and binding locations while incorporating real-world constraints.

Sign in to read the full notes

Get access to AI-generated notes, topic timestamps, and more.

Chai Discovery's Bitter Lesson: Drug Design Is Another Scaling Problem

Simplicity as a Core Principle00:00

Chai Discovery's Mission00:30

Engineering vs. Testing Boundary02:00

Sign in to read the full notes